<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Kastrati, Adnan</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">ISAR-REACT 4 – Bivalirudin Similar to Abciximab/Heparin in Reducing Ischemic Outcomes in NSTEMI and Has Significantly Less Bleeding</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-15</style></pages><abstract><style  face="normal" font="default" size="100%">A strategy of intravenous abciximab (a glycoprotein [GP] IIb/IIIa inhibitor) plus unfractionated heparin, compared with bivalirudin, an IV direct thrombin inhibitor, failed to improve clinical outcomes and increased the risk of bleeding in patients with acute non-ST-segment elevation myocardial infarction (NSTEMI) who were undergoing percutaneous coronary intervention, according to results of the ISAR-REACT 4 trial [NCT00373451].</style></abstract><number><style face="normal" font="default" size="100%">15</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>